ethylenediaminetetraacetic acid nanoparticle + anti-elastin antibody

Ethylenediaminetetraacetic acid (EDTA) nanoparticle + anti-elastin antibody is an experimental targeted chelation therapy developed by researchers at Clemson University and licensed to Elastrin Therapeutics. The drug consists of EDTA-loaded albumin nanoparticles conjugated with anti-elastin antibodies that specifically target damaged or degraded elastin in the calcified elastic lamina of blood vessels. This nanoparticle-based biologic modality is designed to treat medial arterial calcification (MAC), also known as Mönckeberg's sclerosis, which is a common complication in patients with chronic kidney disease and diabetes. By delivering the chelating agent EDTA directly to the site of elastin degradation, the therapy removes calcium deposits and suppresses osteogenic gene expression in vascular smooth muscle cells, potentially reversing arterial stiffness while avoiding the systemic side effects and frequent infusions required by traditional non-specific EDTA chelation therapy.

Other names

EDTA nanoparticle + anti-elastin antibodytargeted EDTA chelation therapyanti-elastin conjugated EDTA nanoparticles